Cynata Therapeutics

Gain a direct line to Cynata Therapeutics leadership

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Contact Us

Pre-Clinical Development

Clinical Development

Products & Pipeline

Scientific Publications

Intellectual Property

Cymerus™ Platform

Our technology

Board of Directors

About us

Company FAQs

Corporate Governance

Analyst Research

Investor FAQs

Financial Reports

Right to Receive Documents

Investor Presentations

Share Price

Announcements

Investors

Updates

Home

Frank Ruhl Libre

Read full article

The immune-mediated tissue destruction of graft-vs-host disease (GvHD) remains a major barrier to greater use of hematopoietic stem cell transplantation (HSCT). Mesenchymal stem cells (MSCs) have intrinsic immunosuppressive qualities and are being actively investigated as a therapeutic strategy for treating GvHD. We characterized Cymerus™ MSCs, which are derived from adult, induced pluripotent stem cells (iPSCs), and show they display surface markers and tri-lineage differentiation consistent with MSCs isolated from bone marrow (BM). Administering iPSC-MSCs altered phosphorylation and cellular localization of the T cell-specific kinase, Protein Kinase C theta (PKCθ), attenuated disease severity, and prolonged survival in a humanized mouse model of GvHD. Finally, we evaluated a constellation of pro-inflammatory molecules on circulating PBMCs that correlated closely with disease progression and which may serve as biomarkers to monitor therapeutic response. Altogether, our data suggest Cymerus iPSC-MSCs offer the potential for an off-the-shelf, cell-based therapy to treat GvHD.

Learn more about hematopoietic stem cell transplantation from ScienceDirect's AI-generated Topic Pages

Learn more about Mesenchymal stem cells from ScienceDirect's AI-generated Topic Pages

Learn more about immunosuppressive from ScienceDirect's AI-generated Topic Pages

Learn more about induced pluripotent stem cells from ScienceDirect's AI-generated Topic Pages

Learn more about surface from ScienceDirect's AI-generated Topic Pages

Learn more about cellular localization from ScienceDirect's AI-generated Topic Pages

Learn more about Protein Kinase C from ScienceDirect's AI-generated Topic Pages

Learn more about humanized mouse from ScienceDirect's AI-generated Topic Pages

Learn more about disease progression from ScienceDirect's AI-generated Topic Pages

Cymerus™ iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease